| Active Not Recruiting | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Are Alopecia Areata | Phase 2 | 2024-04-02 |
| Active Not Recruiting | A Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Se Moderate to Severe Atopic Dermatitis | Phase 2 | 2023-11-15 |
| Terminated | NKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell Ly Non-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-cell Lymphoma | Phase 2 / Phase 3 | 2022-12-23 |
| Completed | A Phase I Study of LY3471851 in Healthy Participants Healthy | Phase 1 | 2022-10-05 |
| Terminated | BEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36) Metastatic Head and Neck Cancer, Recurrent Head and Neck Cancer | Phase 2 / Phase 3 | 2022-03-09 |
| Completed | A Single-Dose Study of LY3471851 in Healthy Participants Healthy | Phase 1 | 2021-08-16 |
| Terminated | A Study of LY3471851 in Adult Participants With Moderately to Severely Active Ulcerative Colitis (UC) Colitis, Ulcerative | Phase 2 | 2021-03-22 |
| Completed | A Placebo Controlled Trial of Bempegaldesleukin (BEMPEG; NKTR-214) With Standard of Care in Patients With Mild Covid-19, Coronavirus Disease 2019 | Phase 1 | 2020-11-13 |
| Completed | Study of NKTR 255 in Combination With Cetuximab in Solid Tumors Head and Neck Squamous Cell Carcinoma, Colorectal Cancer | Phase 1 / Phase 2 | 2020-10-30 |
| Completed | A Study of LY3471851 in Adults With Systemic Lupus Erythematosus (SLE) Systemic Lupus Erythematosus | Phase 2 | 2020-08-19 |
| Terminated | Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Co Melanoma, Melanoma Stage III, Melanoma Stage IV | Phase 3 | 2020-07-27 |
| Completed | A Study of LY3471851 in Participants With Eczema Dermatitis, Atopic | Phase 1 | 2019-12-04 |
| Completed | A Study of LY3471851 in Participants With Psoriasis Psoriasis | Phase 1 | 2019-11-26 |
| Completed | A Study of LY3471851 in Healthy Participants Healthy | Phase 1 | 2019-10-29 |
| Completed | NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma Multiple Myeloma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma | Phase 1 | 2019-10-07 |
| Withdrawn | A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients Metastatic Melanoma | Phase 1 | 2019-08-01 |
| Completed | A Single-Arm Study of Bempegaldesleukin (NKTR-214) Plus Nivolumab in Cisplatin Ineligible Patients Who Have Lo Urinary Bladder Neoplasm, Neoplasm Metastasis | Phase 2 | 2019-04-29 |
| Terminated | A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 3 | 2018-12-18 |
| Terminated | A Study Using fMRI Imaging to Evaluate the Effect of NKTR-181 on Brain Activity in Healthy, Non-physically Dep Moderate to Severe Chronic Pain | Phase 1 | 2018-10-22 |
| Completed | A Study of NKTR-358 (LY3471851) in Participants With Systemic Lupus Erythematosus (SLE) Systemic Lupus Erythematosus | Phase 1 | 2018-04-18 |
| Terminated | REVEAL Study of NKTR-262 in Combination With NKTR-214 and Nivolumab in Patients With Locally Advanced / Metast Melanoma, Merkel Cell Carcinoma, Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2018-03-15 |
| Terminated | Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumor Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | 2017-06-09 |
| Completed | A Study of NKTR-358 (LY3471851) in Healthy Participants Healthy | Phase 1 | 2017-03-19 |
| Completed | A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer T Melanoma, Renal Cell Carcinoma, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | 2016-12-19 |
| Completed | A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metasta Metastasis, Breast Cancer | Phase 3 | 2016-11-01 |
| Completed | A Phase 1/2 Multicenter Dose Escalation and Expansion Study Of NKTR-214 In Subjects With Locally Advanced Or M Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 / Phase 2 | 2015-12-01 |
| Completed | Long-Term Safety and Tolerability Study of NKTR-181 in Subjects With Chronic Low Back Pain or Chronic Non-Canc Low Back Pain, Chronic Pain | Phase 3 | 2015-04-14 |
| Completed | Efficacy and Safety Study of NKTR-181 in Opioid-Naive Subjects With Low Back Pain Low Back Pain, Chronic Pain | Phase 3 | 2015-03-11 |
| Completed | A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Advanced Cancer, Metastatic Solid Tumors | Phase 1 | 2014-02-01 |
| Completed | A Study in Cancer Patients With Hepatic Impairment to Evaluate the Pharmacokinetics and Safety of NKTR-102 (Et Advanced or Metastatic Solid Tumors in Patients With Hepatic Impairment | Phase 1 | 2013-11-01 |
| Completed | A Phase 2 Study To Assess The Efficacy, Tolerability, And Safety OF NKTR-181 In Subjects With Chronic OA Knee Osteoarthritis of the Knee | Phase 2 | 2012-06-01 |
| Completed | The BEACON Study (Breast Cancer Outcomes With NKTR-102) Locally Recurrent Breast Cancer, Metastatic Breast Cancer | Phase 3 | 2011-12-01 |
| Completed | An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies Malignant Solid Tumor | Phase 2 | 2011-10-01 |
| Completed | NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer Colorectal Cancer | Phase 2 | 2008-12-01 |
| Completed | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast C Tumor, Breast Cancer | Phase 2 | 2008-10-01 |
| Completed | Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Tumor, Ovarian Cancer | Phase 2 | 2008-10-01 |
| Completed | NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or L Tumor, Colorectal Cancer | Phase 2 | 2008-02-01 |